Morgan Stanley analyst Michael E Ulz reiterated an Equalweight rating and $5.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT)

The analyst commented, " Kresladi approval marks the company’s first approved GT, highlighting ability to execute and bring treatments to market, which provides positive readthrough to the broader pipeline. Additionally, PRV adds a potential source of non-dilutive capital that could extend the cash runway into early 2028."

For an analyst ratings summary and ratings history on Rocket Pharmaceuticals click here. For more ratings news on Rocket Pharmaceuticals click here.

Shares of Rocket Pharmaceuticals closed at $4.69 yesterday.